Indivior Pharmaceuticals, Inc. Common Stock (INDV) Stock Price

INDVStock

$32.45+31.43%52W

Market Cap$3.83B

P/E18.24x

PEG Ratio—

Div yield—

Beta0.50

INDV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.48%

Price vs S&P 500 (4W)-7.34%

VGM Score52.17

P/E Ratio (Annual)18.24x

P/CF (Annual)124.56x

Book Value / Share (Quarterly)$0.07

P/TBV (Annual)14.91x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)11.20%

Cash Flow / Share (Quarterly)$-0.92

Price vs S&P 500 (YTD)-21.49%

Gross Margin (TTM)81.98%

Net Profit Margin (TTM)26.65%

EPS (TTM)$2.78

10-Day Avg Trading Volume3.17M

EPS Excl Extra (TTM)$2.78

Revenue Growth (5Y)13.88%

EPS (Annual)$1.64

ROI (Annual)-13.72%

Gross Margin (Annual)84.10%

Net Profit Margin (5Y Avg)5.27%

Cash / Share (Quarterly)$1.88

P/E Basic Excl Extra (TTM)10.79x

Revenue Growth QoQ (YoY)13.58%

EPS Growth (5Y)-52.00%

P/E Normalized (Annual)18.24x

ROA (Last FY)17.49%

Revenue Growth TTM (YoY)13.55%

EBITD / Share (TTM)$3.21

ROE (5Y Avg)62.61%

Operating Margin (TTM)30.26%

Cash Flow / Share (Annual)$-0.75

P/B Ratio383.01x

P/B Ratio (Quarterly)230.24x

Net Income / Employee (Annual)$253,900

EV / Revenue (TTM)3.07x

Net Interest Coverage (TTM)11.39x

ROA (TTM)28.14%

EPS Growth QoQ (YoY)588.52%

EV / EBITDA (TTM)9.94x

EPS Incl Extra (Annual)$1.64

Current Ratio (Annual)0.71x

Quick Ratio (Quarterly)0.65x

3-Month Avg Trading Volume2.16M

52-Week Price Return31.43%

EV / Free Cash Flow (Annual)872.26x

P/E Incl Extra (TTM)10.79x

Revenue / Employee (TTM)$1,610,600

Tangible BV / Share (Quarterly)$1.16

P/S Ratio (Annual)3.09x

Asset Turnover (Annual)1.03x

52-Week High$42.81

Operating Margin (5Y Avg)5.27%

EPS Excl Extra (Annual)$1.64

CapEx CAGR (5Y)75.71%

26-Week Price Return-1.58%

Quick Ratio (Annual)0.51x

13-Week Price Return-19.96%

Total Debt / Equity (Annual)5.43x

Current Ratio (Quarterly)0.84x

Enterprise Value$4.10B

Revenue / Share Growth (5Y)17.00%

Asset Turnover (TTM)1.06x

Revenue / Employee (Annual)$1,498,200

Inventory Turnover (Annual)1.19x

Pretax Margin (Annual)19.29%

Cash / Share (Annual)$1.56

3-Month Return Std Dev30.71%

Gross Margin (5Y Avg)84.52%

Net Income / Employee (TTM)$429,300

EBITDA CAGR (5Y)-33.17%

EBITDA Interim CAGR (5Y)16.34%

ROE (Last FY)-88.24%

Net Interest Coverage (Annual)12.26x

EPS Basic Excl Extra (Annual)$1.64

P/FCF (TTM)17.25x

Receivables Turnover (TTM)5.21x

EV / Free Cash Flow (TTM)36.34x

Total Debt / Equity (Quarterly)27.90x

EPS Incl Extra (TTM)$2.78

Receivables Turnover (Annual)4.89x

ROI (TTM)29.40%

P/S Ratio (TTM)2.88x

Pretax Margin (5Y Avg)4.20%

Revenue / Share (Annual)$9.68

Tangible BV / Share (Annual)$0.86

Forward P/E12.26x

Free OCF CAGR (5Y)-48.94%

Price vs S&P 500 (52W)15.90%

P/E Ratio (TTM)10.79x

EPS Growth TTM (YoY)237.50%

Year-to-Date Return-9.56%

5-Day Price Return-10.01%

EPS Normalized (Annual)$1.64

ROA (5Y Avg)3.81%

Net Profit Margin (Annual)16.95%

Month-to-Date Return-9.48%

EBITD / Share (Annual)$2.05

EPS Growth (3Y)-74.29%

Operating Margin (Annual)21.15%

LT Debt / Equity (Annual)4.65x

P/CF (TTM)24.91x

ROI (5Y Avg)20.83%

P/E Excl Extra (TTM)10.79x

LT Debt / Equity (Quarterly)23.50x

EPS Basic Excl Extra (TTM)$2.78

P/TBV (Quarterly)12.23x

P/B Ratio (Annual)49.56x

Inventory Turnover (TTM)1.61x

Pretax Margin (TTM)29.50%

Book Value / Share (Annual)$0.37

Price vs S&P 500 (13W)-22.64%

Net Margin Growth (5Y)-57.03%

Beta0.50x

P/FCF (Annual)766.03x

Revenue / Share (TTM)$10.74

ROE (TTM)159.06%

52-Week Low$23.72

vGradeC

gGradeC

mGradeB

vgmGradeC

INDV Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	$0.92	$1.15	+24.76%(+$0.23)
Q1 2026	Apr 30, 2026	$0.66	$0.96	+45.45%(+$0.30)
Q4 2025	Feb 26, 2026	$0.67	$0.82	+21.66%(+$0.15)
Q3 2025	Oct 30, 2025	$0.41	$0.72	+74.90%(+$0.31)
Q2 2025	Jul 31, 2025	$0.25	$0.51	+104.00%(+$0.26)

INDV Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.20

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
INDVIndivior Pharmaceuticals, Inc. Common Stock	C	C	B	2.9x	13.6%	82.0%	-52.0%	$32.45
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Indivior Pharmaceuticals, Inc. Common Stock

Indivior Pharmaceuticals specializes in treating opioid use disorder (OUD) through buprenorphine-based pharmaceutical products. Its primary revenue sources are Sublocade, an extended-release monthly injection, and Suboxone, a sublingual film combining buprenorphine and naloxone. The company addresses a significant therapeutic need in the management of opioid dependence as a chronic, treatable medical condition.

INDV Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$1.12

Revenue estimate$329.35M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

INDV Insider Transactions

BuyAug 27, 2026
ANDERSON WOODROW D
Officer
Shares: 1,500Value: $53,535
BuyAug 5, 2026
ANDERSON WOODROW D
Officer
Shares: 1,500Value: $54,420

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

PRMPerimeter Solutions, Inc.Chemicals
DFTXDefinium Therapeutics, Inc. Common SharesPharmaceutical Preparations
CBTCabot CorporationIndustrial Chemicals
ADPTAdaptive Biotechnologies Corporation Common StockBiological Products
IPARInterparfums, Inc. Common StockCosmetics & Toiletries
AVNTAvient CorporationPlastics & Resins
RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$23.72

High$42.81